Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Summary

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Timeline

Start

2006-12

Primary completion

2006-12

Completion

2006-12

Outcome

Outcome not reported

Stopped: “Undefined.”

Drugs

Indications